US Edition
The European Commission (EC) Approves Eylea 8 mg for Extended Treatment Intervals of Up to 6 Months
Summary by Eyewire+
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
The European Commission (EC) Approves Eylea 8 mg for Extended Treatment Intervals of Up to 6 Months
The European Commission (EC) has granted a label extension in the European Union (EU) for Eylea 8 mg with extended treatment intervals of up to 6 months for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Eylea 8 mg was previously approved for administration at extended treatment intervals of up to every 4 months, following 3 initial monthly doses. Eylea 8 mg is the first and only anti-vascular endot…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
